GlassScriptPhysician profile
Jason M Couture
NPI 1962609115
$3,402.87
in general payments reported to CMS, 2019-2025
27 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $319 · 2021: $865 · 2022: $630 · 2023: $333 · 2024: $433 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $617.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $532.05 | 2021-2024 | Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $287.17 | 2019-2025 | |
| Pfizer INC. | $285.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $245.43 | 2019-2024 | Shingrix |
| Lilly USA, LLC | $212.63 | 2020-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $149.09 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $124.34 | 2021-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $117.28 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $108.04 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.63 | 2019-2025 | Xifaxan |
| Amgen INC. | $79.03 | 2020-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $69.05 | 2021-2023 | |
| Allergan, INC. | $67.53 | 2020 | |
| Merck Sharp & Dohme LLC | $67.18 | 2019-2023 | Verquvo, Steglatro, Belsomra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $59.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.18 | 2021 | |
| Astellas Pharma US INC | $35.00 | 2023 | Veozah |
| Boston Scientific Corporation | $34.83 | 2024-2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $26.97 | 2020-2021 | |
| Alkermes, INC. | $22.96 | 2019 | |
| Biosense Webster, INC. | $20.74 | 2021 | |
| Nevro Corp. | $20.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.64 | 2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $18.92 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $17.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.79 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Couture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.